Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplant.

Prockop S, Doubrovina E, Suser S, Heller G, Barker J, Dahi P, Perales MA, Papadopoulos E, Sauter C, Castro-Malaspina H, Boulad F, Curran KJ, Giralt S, Gyurkocza B, Hsu KC, Jakubowski A, Hanash AM, Kernan NA, Kobos R, Koehne G, Landau H, Ponce D, Spitzer B, Young JW, Behr G, Dunphy M, Haque S, Teruya-Feldstein J, Arcila M, Moung C, Hsu S, Hasan A, O'Reilly RJ.

J Clin Invest. 2019 Nov 5. pii: 121127. doi: 10.1172/JCI121127. [Epub ahead of print]

2.

Favorable long-term outcomes of hematopoietic stem cell transplantation for CMML with myeloablative conditioning, anti-thymocyte globulin, and CD34+ selected graft.

Lin RJ, Sanchez M, Abbi K, Devlin SM, Jakubowski AA, Papadopoulos EB, Barker JN, Tamari R, Young JW, Gyurkocza B, Ponce DM, Dahi PB, Maloy MA, Giralt SA, Perales MA, Castro-Malaspina H.

Bone Marrow Transplant. 2019 Oct 23. doi: 10.1038/s41409-019-0723-x. [Epub ahead of print] No abstract available.

PMID:
31645667
3.

Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease.

Montoro J, Ceberio I, Hilden P, Maloy MA, Barker J, Castro-Malaspina H, Dahi P, Koehne G, Perales MA, Ponce D, Sauter C, Shaffer B, Tamari R, Young JW, Giralt SA, O'Reilly RJ, Jakubowski AA, Papadopoulos EB.

Biol Blood Marrow Transplant. 2019 Oct 13. pii: S1083-8791(19)30659-7. doi: 10.1016/j.bbmt.2019.10.003. [Epub ahead of print]

PMID:
31618690
4.

Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation.

Scordo M, Bhatt V, Hilden P, Smith M, Thoren K, Cho C, Shah GL, Maloy MA, Papadopoulos EB, Jakubowski AA, Avecilla ST, O'Reilly RJ, Castro-Malaspina H, Tamari R, Shaffer BC, Boelens JJ, Perales MA, Giralt SA.

Biol Blood Marrow Transplant. 2019 Aug;25(8):1526-1535. doi: 10.1016/j.bbmt.2019.02.021. Epub 2019 Mar 1.

PMID:
30831208
5.

Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis.

Tamari R, Rapaport F, Zhang N, McNamara C, Kuykendall A, Sallman DA, Komrokji R, Arruda A, Najfeld V, Sandy L, Medina J, Litvin R, Famulare CA, Patel MA, Maloy M, Castro-Malaspina H, Giralt SA, Weinberg RS, Mascarenhas JO, Mesa R, Rondelli D, Dueck AC, Levine RL, Gupta V, Hoffman R, Rampal RK.

Biol Blood Marrow Transplant. 2019 Jun;25(6):1142-1151. doi: 10.1016/j.bbmt.2019.01.002. Epub 2019 Jan 6.

PMID:
30625392
6.

Immune Cytopenias after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation.

Scordo M, Hsu M, Jakubowski AA, Shah GL, Cho C, Maloy MA, Avecilla ST, Papadopoulos EB, Gyurkocza B, Castro-Malaspina H, Tamari R, O'Reilly RJ, Perales MA, Giralt SA, Shaffer BC.

Biol Blood Marrow Transplant. 2019 Jun;25(6):1136-1141. doi: 10.1016/j.bbmt.2018.12.842. Epub 2019 Jan 6.

PMID:
30625387
7.

Burden and impact of multifactorial geriatric syndromes in allogeneic hematopoietic cell transplantation for older adults.

Lin RJ, Hilden PD, Elko TA, Dahi PB, Shahrokni A, Jakubowski AA, Perales MA, Sauter CS, Castro-Malaspina HR, Barker JN, Shaffer BC, Tamari R, Papadopoulos EB, Maloy MA, Korc-Grodzicki B, Giralt SA.

Blood Adv. 2019 Jan 8;3(1):12-20. doi: 10.1182/bloodadvances.2018028241.

8.

Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations.

Lin RJ, Ho C, Hilden PD, Barker JN, Giralt SA, Hamlin PA, Jakubowski AA, Castro-Malaspina HR, Robinson KS, Papadopoulos EB, Perales MA, Sauter CS.

Br J Haematol. 2019 Mar;184(6):1006-1010. doi: 10.1111/bjh.15721. Epub 2018 Dec 11.

PMID:
30537212
9.

Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC.

Malard F, Labopin M, Cho C, Blaise D, Papadopoulos EB, Passweg J, O'Reilly R, Forcade E, Maloy M, Volin L, Castro-Malaspina H, Hicheri Y, Jakubowski AA, Orvain C, Giralt S, Mohty M, Nagler A, Perales MA.

J Hematol Oncol. 2018 Oct 20;11(1):127. doi: 10.1186/s13045-018-0668-3.

10.

Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant.

Taur Y, Coyte K, Schluter J, Robilotti E, Figueroa C, Gjonbalaj M, Littmann ER, Ling L, Miller L, Gyaltshen Y, Fontana E, Morjaria S, Gyurkocza B, Perales MA, Castro-Malaspina H, Tamari R, Ponce D, Koehne G, Barker J, Jakubowski A, Papadopoulos E, Dahi P, Sauter C, Shaffer B, Young JW, Peled J, Meagher RC, Jenq RR, van den Brink MRM, Giralt SA, Pamer EG, Xavier JB.

Sci Transl Med. 2018 Sep 26;10(460). pii: eaap9489. doi: 10.1126/scitranslmed.aap9489.

11.

Early Fluid Overload Is Associated with an Increased Risk of Nonrelapse Mortality after Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation.

Rondon-Clavo C, Scordo M, Hilden P, Shah GL, Cho C, Maloy MA, Papadopoulos EB, Jakubowski AA, O'Reilly RJ, Gyurkocza B, Castro-Malaspina H, Tamari R, Shaffer BC, Perales MA, Jaimes EA, Giralt SA.

Biol Blood Marrow Transplant. 2018 Dec;24(12):2517-2522. doi: 10.1016/j.bbmt.2018.07.031. Epub 2018 Jul 26.

PMID:
30055353
12.

Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation.

Tamari R, Oran B, Hilden P, Maloy M, Kongtim P, Papadopoulos EB, Rondon G, Jakubowski AA, Andersson BS, Devlin SM, Ahmed S, Popat UR, Ponce D, Chen J, Sauter C, Young JW, de Lima M, Perales MA, O'Reilly RJ, Giralt SA, Champlin RE, Castro-Malaspina H.

Biol Blood Marrow Transplant. 2018 May;24(5):1079-1087. doi: 10.1016/j.bbmt.2018.01.001. Epub 2018 Jan 8.

13.

CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome .

Barba P, Martino R, Zhou Q, Cho C, Castro-Malaspina H, Devlin S, Esquirol A, Giralt S, Jakubowski AA, Caballero D, Maloy M, Papadopoulos EB, Piñana JL, Fox ML, Márquez-Malaver FJ, Valcárcel D, Solano C, López-Corral L, Sierra J, Perales MA.

Biol Blood Marrow Transplant. 2018 May;24(5):964-972. doi: 10.1016/j.bbmt.2017.12.804. Epub 2018 Jan 2.

14.

Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis.

Cho C, Hsu M, Barba P, Maloy MA, Avecilla ST, Barker JN, Castro-Malaspina H, Giralt SA, Jakubowski AA, Koehne G, Meagher RC, O'Reilly RJ, Papadopoulos EB, Ponce DM, Tamari R, van den Brink MRM, Young JW, Devlin SM, Perales MA.

Bone Marrow Transplant. 2017 Dec;52(12):1629-1636. doi: 10.1038/bmt.2017.197. Epub 2017 Oct 9.

15.

Impact of Toxicity on Survival for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation.

Shah GL, Scordo M, Kosuri S, Herrera DA, Cho C, Devlin SM, Borrill T, Carlow DC, Avecilla ST, Meagher RC, O'Reilly RJ, Jakubowski AA, Papadopoulos EB, Koehne G, Gyurkocza B, Castro-Malaspina H, Shaffer BC, Perales MA, Giralt SA, Tamari R.

Biol Blood Marrow Transplant. 2018 Jan;24(1):142-149. doi: 10.1016/j.bbmt.2017.08.040. Epub 2017 Sep 22.

16.

Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation.

Scordo M, Shah GL, Kosuri S, Herrera DA, Cho C, Devlin SM, Maloy MA, Nieves J, Borrill T, Avecilla ST, Meagher RC, Carlow DC, O'Reilly RJ, Papadopoulos EB, Jakubowski AA, Koehne G, Gyurkocza B, Castro-Malaspina H, Tamari R, Perales MA, Giralt SA, Shaffer BC.

Biol Blood Marrow Transplant. 2018 Jan;24(1):133-141. doi: 10.1016/j.bbmt.2017.08.033. Epub 2017 Sep 1.

17.

T Cell Depletion as an Alternative Approach for Patients 55 Years or Older Undergoing Allogeneic Stem Cell Transplantation as Curative Therapy for Hematologic Malignancies.

Jakubowski AA, Petrlik E, Maloy M, Hilden P, Papadopoulos E, Young JW, Boulad F, Castro-Malaspina H, Tamari R, Dahi PB, Goldberg J, Koehne G, Perales MA, Sauter CS, O'Reilly RJ, Giralt S.

Biol Blood Marrow Transplant. 2017 Oct;23(10):1685-1694. doi: 10.1016/j.bbmt.2017.06.024. Epub 2017 Jul 19.

18.

The Impact of Toxicities on First-Year Outcomes after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies.

Kosuri S, Adrianzen Herrera D, Scordo M, Shah GL, Cho C, Devlin SM, Maloy MA, Nieves J, Borrill T, Carlow DC, Avecilla ST, Meagher RC, O'Reilly RJ, Papadopoulos EB, Jakubowski AA, Koehne G, Gyurkocza B, Castro-Malaspina H, Shaffer BC, Tamari R, Giralt SA, Perales MA.

Biol Blood Marrow Transplant. 2017 Nov;23(11):2004-2011. doi: 10.1016/j.bbmt.2017.07.012. Epub 2017 Jul 18.

19.

A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.

Spitzer B, Jakubowski AA, Papadopoulos EB, Fuller K, Hilden PD, Young JW, Barker JN, Koehne G, Perales MA, Hsu KC, van den Brink MR, Kernan NA, Prockop SE, Scaradavou A, Castro-Malaspina H, O'Reilly RJ, Boulad F.

Biol Blood Marrow Transplant. 2017 Dec;23(12):2088-2095. doi: 10.1016/j.bbmt.2017.07.004. Epub 2017 Jul 12.

20.

Allogeneic Hematopoietic Stem Cell Transplantation Is Underutilized in Older Patients with Myelodysplastic Syndromes.

Getta BM, Kishtagari A, Hilden P, Tallman MS, Maloy M, Gonzales P, Castro-Malaspina H, Perales MA, Giralt S, Tamari R, Klimek V.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1078-1086. doi: 10.1016/j.bbmt.2017.03.020. Epub 2017 Mar 20.

21.

Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant.

Goldberg JD, Zheng J, Ratan R, Small TN, Lai KC, Boulad F, Castro-Malaspina H, Giralt SA, Jakubowski AA, Kernan NA, O'Reilly RJ, Papadopoulos EB, Young JW, van den Brink MR, Heller G, Perales MA.

Leuk Lymphoma. 2017 Aug;58(8):1859-1871. doi: 10.1080/10428194.2016.1265113. Epub 2017 Jan 10.

22.

Ex Vivo CD34+-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response.

Barba P, Hilden P, Devlin SM, Maloy M, Dierov D, Nieves J, Garrett MD, Sogani J, Cho C, Barker JN, Kernan NA, Castro-Malaspina H, Jakubowski AA, Koehne G, Papadopoulos EB, Prockop S, Sauter C, Tamari R, van den Brink MR, Avecilla ST, Meagher R, O'Reilly RJ, Goldberg JD, Young JW, Giralt S, Perales MA, Ponce DM.

Biol Blood Marrow Transplant. 2017 Mar;23(3):452-458. doi: 10.1016/j.bbmt.2016.12.633. Epub 2016 Dec 23.

23.

Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34+ Selected Grafts for Allogeneic Hematopoietic Cell Transplantation.

Barba P, Ratan R, Cho C, Ceberio I, Hilden P, Devlin SM, Maloy MA, Barker JN, Castro-Malaspina H, Jakubowski AA, Koehne G, Papadopoulos EB, Ponce DM, Sauter C, Tamari R, van den Brink MRM, Young JW, O'Reilly RJ, Giralt SA, Perales MA.

Biol Blood Marrow Transplant. 2017 Jan;23(1):67-74. doi: 10.1016/j.bbmt.2016.10.017. Epub 2016 Oct 24.

24.

Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa.

Spitzer B, Perales MA, Kernan NA, Prockop SE, Zabor EC, Webb N, Castro-Malaspina H, Papadopoulos EB, Young JW, Scaradavou A, Kobos R, Giralt SA, O'Reilly RJ, Boulad F.

Biol Blood Marrow Transplant. 2016 Aug;22(8):1449-1454. doi: 10.1016/j.bbmt.2016.05.001. Epub 2016 May 13.

25.

Cytomegalovirus Infection after CD34(+)-Selected Hematopoietic Cell Transplantation.

Huang YT, Neofytos D, Foldi J, Kim SJ, Maloy M, Chung D, Castro-Malaspina H, Giralt SA, Papadopoulos E, Perales MA, Jakubowski AA, Papanicolaou GA.

Biol Blood Marrow Transplant. 2016 Aug;22(8):1480-1486. doi: 10.1016/j.bbmt.2016.05.003. Epub 2016 May 10.

26.

A novel reduced intensity conditioning regimen for patients with high-risk hematological malignancies undergoing allogeneic stem cell transplantation.

Hobbs GS, Kaur N, Hilden P, Ponce D, Cho C, Castro-Malaspina HR, Giralt S, Goldberg JD, Jakubowski AA, Papadopoulos EB, Sauter C, Koehne G, Yahalom J, Delvin S, Barker JN, Perales MA.

Bone Marrow Transplant. 2016 Jul;51(7):1010-2. doi: 10.1038/bmt.2016.36. Epub 2016 Mar 14. No abstract available.

27.

Low incidence of GvHD with T-cell depleted allografts facilitates further treatments for post-transplantation relapse in AML and MDS.

Dahi PB, Morawa E, Perales MA, Zabor EC, Devlin SM, Maloy M, Castro-Malaspina H, O'Reilly RJ, Papadopoulos EB, Jakubowski AA, Giralt SA.

Bone Marrow Transplant. 2016 Jul;51(7):991-3. doi: 10.1038/bmt.2016.23. Epub 2016 Feb 29. No abstract available.

28.

The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months.

Lunning MA, Migliacci JC, Hilden P, Devlin SM, Castro-Malaspina H, Giralt S, Perales MA, Zelenetz AD, Moskowitz CH, Sauter CS.

Br J Haematol. 2016 Apr;173(2):260-4. doi: 10.1111/bjh.13947. Epub 2016 Feb 5.

29.

High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia.

Ponce DM, Hilden P, Devlin SM, Maloy M, Lubin M, Castro-Malaspina H, Dahi P, Hsu K, Jakubowski AA, Kernan NA, Koehne G, O'Reilly RJ, Papadopoulos EB, Perales MA, Sauter C, Scaradavou A, Tamari R, van den Brink MR, Young JW, Giralt S, Barker JN.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1985-93. doi: 10.1016/j.bbmt.2015.07.029. Epub 2015 Jul 31.

30.

CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse.

Tamari R, Chung SS, Papadopoulos EB, Jakubowski AA, Hilden P, Devlin SM, Goldberg JD, Perales MA, Ponce DM, Sauter CS, Maloy MA, Herman DY, Klimek V, Young JW, O'Reilly RJ, Giralt SA, Castro-Malaspina H.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2106-2114. doi: 10.1016/j.bbmt.2015.07.010. Epub 2015 Jul 14.

31.

Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era.

Mussetti A, Devlin SM, Castro-Malaspina HR, Barker JN, Giralt SA, Zelenetz AD, Sauter CS, Perales MA.

Bone Marrow Transplant. 2015 Oct;50(10):1293-1298. doi: 10.1038/bmt.2015.156. Epub 2015 Jul 6.

32.

Transplant for MDS: challenges and emerging strategies.

Tamari R, Castro-Malaspina H.

Best Pract Res Clin Haematol. 2015 Mar;28(1):43-54. doi: 10.1016/j.beha.2014.11.006. Epub 2014 Dec 4. Review.

PMID:
25659729
33.

Allogeneic haematopoietic stem cell transplantation for primary myelofibrosis and myelofibrosis evolved from other myeloproliferative neoplasms.

Tamari R, Castro-Malaspina H.

Curr Opin Hematol. 2015 Mar;22(2):184-90. doi: 10.1097/MOH.0000000000000121. Review.

PMID:
25635756
34.

Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT.

Ceberio I, Dai K, Devlin SM, Barker JN, Castro-Malaspina H, Goldberg JD, Giralt S, Adel NG, Perales MA.

Bone Marrow Transplant. 2015 Mar;50(3):438-43. doi: 10.1038/bmt.2014.286. Epub 2015 Jan 19.

35.

Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.

Ceberio I, Devlin SM, Sauter C, Barker JN, Castro-Malaspina H, Giralt S, Ponce DM, Lechner L, Maloy MA, Goldberg JD, Perales MA.

Leuk Lymphoma. 2015 Mar;56(3):663-70. doi: 10.3109/10428194.2014.930851. Epub 2014 Aug 6.

36.

Pretransplantation fluorine-18-deoxyglucose--positron emission tomography scan lacks prognostic value in chemosensitive B cell non-hodgkin lymphoma patients undergoing nonmyeloablative allogeneic stem cell transplantation.

Sauter CS, Lechner L, Scordo M, Zheng J, Devlin SM, Fleming SE, Castro-Malaspina H, Moskowitz CH.

Biol Blood Marrow Transplant. 2014 Jun;20(6):881-4. doi: 10.1016/j.bbmt.2014.02.009. Epub 2014 Feb 15.

37.

A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignancies.

Sauter CS, Chou JF, Papadopoulos EB, Perales MA, Jakubowski AA, Young JW, Scordo M, Giralt S, Castro-Malaspina H.

Leuk Lymphoma. 2014 Dec;55(12):2739-47. doi: 10.3109/10428194.2014.894185. Epub 2014 Mar 20.

38.

A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.

Sauter CS, Barker JN, Lechner L, Zheng J, Devlin SM, Papadopoulos EB, Perales MA, Jakubowski AA, Goldberg JD, Koehne G, Ceberio I, Giralt S, Zelenetz AD, Moskowitz CH, Castro-Malaspina H.

Biol Blood Marrow Transplant. 2014 Mar;20(3):354-60. doi: 10.1016/j.bbmt.2013.11.029. Epub 2013 Dec 4.

39.

A prospective multicenter study of paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure.

Raza A, Ravandi F, Rastogi A, Bubis J, Lim SH, Weitz I, Castro-Malaspina H, Galili N, Jawde RA, Illingworth A.

Cytometry B Clin Cytom. 2014 May;86(3):175-82. doi: 10.1002/cyto.b.21139. Epub 2013 Nov 12.

40.

A Prospective Multicenter Study of Paroxysmal Nocturnal Hemoglobinuria Cells in Patients with Bone Marrow Failure.

Raza A, Ravandi F, Rastogi A, Bubis J, Lim SH, Weitz I, Castro-Malaspina H, Galili N, Jawde RA, Illingworth A.

Cytometry B Clin Cytom. 2013 Oct 11. doi: 10.1002/cytob.21139. [Epub ahead of print]

41.

Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.

Bayraktar UD, de Lima M, Saliba RM, Maloy M, Castro-Malaspina HR, Chen J, Rondon G, Chiattone A, Jakubowski AA, Boulad F, Kernan NA, O'Reilly RJ, Champlin RE, Giralt S, Andersson BS, Papadopoulos EB.

Biol Blood Marrow Transplant. 2013 Jun;19(6):898-903. doi: 10.1016/j.bbmt.2013.02.018. Epub 2013 Mar 1.

42.

Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match.

Ponce DM, Gonzales A, Lubin M, Castro-Malaspina H, Giralt S, Goldberg JD, Hanash AM, Jakubowski A, Jenq R, Papadopoulos EB, Perales MA, van den Brink MR, Young JW, Boulad F, O'Reilly RJ, Prockop S, Small TN, Scaradavou A, Kernan NA, Stevens CE, Barker JN.

Biol Blood Marrow Transplant. 2013 Jun;19(6):904-11. doi: 10.1016/j.bbmt.2013.02.008. Epub 2013 Feb 14.

43.

A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation.

Ponce DM, Sauter C, Devlin S, Lubin M, Gonzales AM, Kernan NA, Scaradavou A, Giralt S, Goldberg JD, Koehne G, Perales MA, Young JW, Castro-Malaspina H, Jakubowski A, Papadopoulos EB, Barker JN.

Biol Blood Marrow Transplant. 2013 May;19(5):799-803. doi: 10.1016/j.bbmt.2013.02.007. Epub 2013 Feb 14.

44.

T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease.

Goldberg JD, Linker A, Kuk D, Ratan R, Jurcic J, Barker JN, Castro-Malaspina H, Giralt S, Hsu K, Jakubowski AA, Jenq R, Koehne G, Papadopoulos EB, van den Brink MR, Young JW, Boulad F, Kernan NA, O'Reilly RJ, Prockop SE, Yahalom J, Heller G, Perales MA.

Biol Blood Marrow Transplant. 2013 Feb;19(2):208-13. doi: 10.1016/j.bbmt.2012.09.003. Epub 2012 Sep 13.

45.

Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants.

Goldberg JD, Zheng J, Castro-Malaspina H, Jakubowski AA, Heller G, van den Brink MR, Perales MA.

Bone Marrow Transplant. 2013 Jan;48(1):99-104. doi: 10.1038/bmt.2012.115. Epub 2012 Jul 2.

46.

Paroxysmal nocturnal hemoglobinuria in pediatric patients.

Curran KJ, Kernan NA, Prockop SE, Scaradavou A, Small TN, Kobos R, Castro-Malaspina H, Araten D, DiMichele D, O'Reilly RJ, Boulad F.

Pediatr Blood Cancer. 2012 Sep;59(3):525-9. doi: 10.1002/pbc.23410. Epub 2011 Dec 6.

PMID:
22147651
47.

Importance of day 21 BM chimerism in sustained neutrophil engraftment following double-unit cord blood transplantation.

Avery S, Voss MH, Gonzales AM, Lubin M, Castro-Malaspina H, Giralt S, Kernan NA, Scaradavou A, Hedvat CV, Stevens CE, Barker JN.

Bone Marrow Transplant. 2012 Aug;47(8):1056-60. doi: 10.1038/bmt.2011.236. Epub 2011 Dec 5.

48.

Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.

Doubrovina E, Oflaz-Sozmen B, Prockop SE, Kernan NA, Abramson S, Teruya-Feldstein J, Hedvat C, Chou JF, Heller G, Barker JN, Boulad F, Castro-Malaspina H, George D, Jakubowski A, Koehne G, Papadopoulos EB, Scaradavou A, Small TN, Khalaf R, Young JW, O'Reilly RJ.

Blood. 2012 Mar 15;119(11):2644-56. doi: 10.1182/blood-2011-08-371971. Epub 2011 Dec 2.

49.

Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant.

Goldberg JD, Chou JF, Horwitz S, Teruya-Feldstein J, Barker JN, Boulad F, Castro-Malaspina H, Giralt S, Jakubowski AA, Koehne G, van den Brink MRM, Young JW, Zhang Z, Papadopoulos EB, Perales MA.

Leuk Lymphoma. 2012 Jun;53(6):1124-1129. doi: 10.3109/10428194.2011.645818. Epub 2012 Jan 31.

50.

Thrombolytic therapy is effective in paroxysmal nocturnal hemoglobinuria: a series of nine patients and a review of the literature.

Araten DJ, Notaro R, Thaler HT, Kernan N, Boulad F, Castro-Malaspina H, Small T, Scaradavou A, Magnan H, Prockop S, Chaffee S, Gonsky J, Thertulien R, Tarquini R, Luzzatto L.

Haematologica. 2012 Mar;97(3):344-52. doi: 10.3324/haematol.2011.049767. Epub 2011 Dec 1. Review.

Supplemental Content

Loading ...
Support Center